The first modern mainstream antibiotic, penicillin, was introduced for common use in 1942. Reports of penicillin resistance began with Staphylococcus aureus isolated in hospitals- in 1942. In 2019, over 2.8 million cases of antimicrobial-resistant (AMR) infections were reported by the CDC in the United States alone, making it a serious global health threat, and prevalence is steadily rising. Our understanding of the AMR phenomenon is constantly advancing, evolving our knowledge of how resistance mechanisms work, what causes drug resistance, how it spreads, and who is affected. This two-part webinar highlights the growing global threat caused by AMR infections. In part two of this webinar, we will provide an overview of the biggest challenges facing the field, progress in diagnosis, research, and development; and further information. We will also show how ATCC is addressing this challenge through its pledge to support global health by developing and improving collections of high-quality biological materials for use in research, diagnostics, drug and product development, and clinical applications.
- Understanding the nature of the problem: explaining the biggest challenges hindering advancement such as financial deficits, implementation of surveillance or new therapies, and the speed of resistance outpacing the speed of scientific research.
- Explaining progress: scientific and clinical advances, how organizations are contributing to the fight against AMR, and how ATCC is contributing to the fight against AMR.